Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE ≤12) for up to six months

David G. Wilkinson, C. Hock, Martin Farlow, B. Van Baelen, S. Schwalen

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We investigated whether galantamine (Reminyl®), a cholinergic agent with a dual mode of action for the treatment of mild to moderate Alzheimer's disease (AD), would benefit patients with more advanced illness. We performed a post hoc analysis on pooled data from four pivotal studies in patients with 'advanced moderate' AD: baseline Mini-Mental State Evaluation (MMSE) scores ≤ 12 (range 10-12; mean MMSE score 11) or Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scores >30 (range 31-69; mean ADAS-cog score 39). Over 5-6 months, cognitive abilities were improved with galantamine versus placebo (p

Original languageEnglish (US)
Pages (from-to)509-514
Number of pages6
JournalInternational Journal of Clinical Practice
Volume56
Issue number7
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Galantamine
Alzheimer Disease
Aptitude
Cholinergic Agents
Placebos
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE ≤12) for up to six months. / Wilkinson, David G.; Hock, C.; Farlow, Martin; Van Baelen, B.; Schwalen, S.

In: International Journal of Clinical Practice, Vol. 56, No. 7, 09.2002, p. 509-514.

Research output: Contribution to journalArticle

@article{a8e85e1b70d7401aa533097341851af7,
title = "Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE ≤12) for up to six months",
abstract = "We investigated whether galantamine (Reminyl{\circledR}), a cholinergic agent with a dual mode of action for the treatment of mild to moderate Alzheimer's disease (AD), would benefit patients with more advanced illness. We performed a post hoc analysis on pooled data from four pivotal studies in patients with 'advanced moderate' AD: baseline Mini-Mental State Evaluation (MMSE) scores ≤ 12 (range 10-12; mean MMSE score 11) or Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scores >30 (range 31-69; mean ADAS-cog score 39). Over 5-6 months, cognitive abilities were improved with galantamine versus placebo (p",
author = "Wilkinson, {David G.} and C. Hock and Martin Farlow and {Van Baelen}, B. and S. Schwalen",
year = "2002",
month = "9",
language = "English (US)",
volume = "56",
pages = "509--514",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE ≤12) for up to six months

AU - Wilkinson, David G.

AU - Hock, C.

AU - Farlow, Martin

AU - Van Baelen, B.

AU - Schwalen, S.

PY - 2002/9

Y1 - 2002/9

N2 - We investigated whether galantamine (Reminyl®), a cholinergic agent with a dual mode of action for the treatment of mild to moderate Alzheimer's disease (AD), would benefit patients with more advanced illness. We performed a post hoc analysis on pooled data from four pivotal studies in patients with 'advanced moderate' AD: baseline Mini-Mental State Evaluation (MMSE) scores ≤ 12 (range 10-12; mean MMSE score 11) or Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scores >30 (range 31-69; mean ADAS-cog score 39). Over 5-6 months, cognitive abilities were improved with galantamine versus placebo (p

AB - We investigated whether galantamine (Reminyl®), a cholinergic agent with a dual mode of action for the treatment of mild to moderate Alzheimer's disease (AD), would benefit patients with more advanced illness. We performed a post hoc analysis on pooled data from four pivotal studies in patients with 'advanced moderate' AD: baseline Mini-Mental State Evaluation (MMSE) scores ≤ 12 (range 10-12; mean MMSE score 11) or Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scores >30 (range 31-69; mean ADAS-cog score 39). Over 5-6 months, cognitive abilities were improved with galantamine versus placebo (p

UR - http://www.scopus.com/inward/record.url?scp=0036735223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036735223&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 509

EP - 514

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 7

ER -